Search

Background: Flurbiprofen 8.75 mg lozenges and oromucosal sprays are used for symptomatic relief of sore throat in patients aged 12 years and over. The documented adverse events of flurbiprofen use include those related to its pharmacological actions, namely, increased risk of haemorrhagic events, however other adverse events (such as nephrotoxicity and cardiac failure) have been known to occur. The likelihood of occurrence of adverse events increases when flurbiprofen is used concomitantly with some other medications. Therefore, the objective of this systematic review was to collate the current evidence on adverse events which occur with flurbiprofen 8.75 mg dose (any formulation), in particular as a result of interaction with other medicinal products, with a focus on non-haemorrhagic events. Methods: Systematic searches of the literature were conducted to identify literature on any formulation of flurbiprofen 8.75 mg up to the date of the electronic database search (data lock: 28 April 2020). Publications were screened to identify studies reporting non-haemorrhagic adverse events with flurbiprofen 8.75 mg and/or non-haemorrhagic adverse events in the comparator arm. Data extraction was performed for eligible studies according to pre-defined criteria and summarised in narratives, tables and figures. Risk of bias and certainty of evidence assessments were planned for each included study where results relating to the primary objective of the systematic review were available. Results: Of 1,528 publications identified by systematic literature searches, 26 met the inclusion criteria and were included in this review. None of these 26 studies contained information on non-haemorrhagic adverse events occurring as a result of a drug-drug interaction (interaction with concomitant medication used with flurbiprofen 8.75 mg), as per the primary objective and secondary objectives of the systematic review. Conclusion: Results from this systematic review on the risk of non-haemorrhagic events did not provide evidence for these events occurring as a result of interaction with other medicinal products. Additional appropriately designed studies would be required to confirm whether these findings suggest a true absence of risk or limitations in reporting. [ABSTRACT FROM AUTHOR]

In all pivotal trials of COVID-19 vaccines, the history of previous SARS-CoV-2 infection was mentioned as one of the main exclusion criteria. In the absence of clinical trials, observational studies are the primary source for evidence generation. This study aims to describe the patient-reported adverse drug reactions (ADRs) following the first COVID-19 vaccination cycle, as well as the administration of booster doses of different vaccine brands, in people with prior SARS-CoV-2 infection, as compared to prior infection-free matched cohorts of vaccinees. A web-based prospective study was conducted collecting vaccinee-reported outcomes through electronic questionnaires from eleven European countries in the period February 2021–February 2023. A baseline questionnaire and up to six follow-up questionnaires collected data on the vaccinee's characteristics, as well as solicited and unsolicited adverse reactions. Overall, 3886 and 902 vaccinees with prior SARS-CoV-2 infection and having received the first dose or a booster dose, respectively, were included in the analysis. After the first dose or booster dose, vaccinees with prior SARS-CoV-2 infection reported at least one ADR at a higher frequency than those matched without prior infection (3470 [89.6%] vs. 2916 [75.3%], and 614 [68.2%] vs. 546 [60.6%], respectively). On the contrary side, after the second dose, vaccinees with a history of SARS-CoV-2 infection reported at least one ADR at a lower frequency, compared to matched controls (1443 [85.0%] vs. 1543 [90.9%]). The median time to onset and the median time to recovery were similar across all doses and cohorts. The frequency of adverse reactions was higher in individuals with prior SARS-CoV-2 infection who received Vaxzevria as the first dose and Spikevax as the second and booster doses. The frequency of serious ADRs was low for all doses and cohorts. Data from this large-scale prospective study of COVID-19 vaccinees could be used to inform people as to the likelihood of adverse effects based on their history of SARS-CoV-2 infection, age, sex, and the type of vaccine administered. In line with pivotal trials, the safety profile of COVID-19 vaccines was also confirmed in people with prior SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]

This research paper represents the estimation and reduction of eddy current loss in a Magnetic Fault Current Limiter (MFCL). The nonlinear model of the device is established using electromagnetic coupled circuit supported by Finite Element Model. The current limiting performance of the MFCL is investigated by simulation study as well as laboratory testing. It is further observed that a significant amount of eddy current loss takes place inside the core and permanent magnet of the device. Different methods (shorting ring, lamination of permanent magnet and variation of magnet length) are proposed to reduce the eddy current. The advantages and disadvantages of these methods are discussed. Some design modifications are also proposed to minimize the temperature rise caused by the eddy current. [ABSTRACT FROM AUTHOR]

Background: Deploying mobile health vans (MHVs) to service disadvantaged, underserved mountainous hamlets across six districts of Uttarakhand on a “fixed day-fixed location” strategy was an effective initiative in the state in collaboration with Technology Information Forecasting and Assessment Council (TIFAC) and NRHM. Aims and Objectives: The aim of the study was to provide quality diagnostic and curative care through mobile health clinics at select mountainous outreaches of Uttarakhand state. Materials and Methods: A bimonthly mobile health services with fully equipped MHV sponsored by the directorate of science and TIFAC and assessment council and Government of Uttarakhand on a “fixed day, fixed time and fixed place” schedule were provided along pre-designated service locations. Results: A total of 77,688 beneficiaries received services through 902 camps spanning 13 quarters with an estimated 5976 and 89 beneficiaries per quarter per camp; 573 clients received ultrasound, 639 X-ray, 34 ECG, and 3543 other lab procedures. Quarterly demand for services was highest, 19.5% for gastrointestinal disorders, followed by 18.4% for musculoskeletal disorders, 13.8% for genitourinary system disorders, 11.8% for respiratory system disorders, and 8.5% for ENT and ocular disorders. The prevalent morbidity was predominantly acid peptic disease (15.5%), followed by osteoarthritis (13.3%) and low backache and renal stones (7.2% each). Conclusion: Integrating mobile health service delivery component with existing strategies adopted by public health system in primary health care is an operationally feasible and viable option to address ‘inaccessibility at disadvantaged mountainous outreach. [ABSTRACT FROM AUTHOR]

This paper presents a mathematical model of a power controller for a high-frequency induction heating system based on a modified half-bridge series resonant inverter. The output real power is precise over the heating coil, and this real power is processed as a feedback signal that contends a closed-loop topology with a proportional-integral-derivative controller. This technique enables both control of the closed-loop power and determination of the stability of the high-frequency inverter. Unlike the topologies of existing power controllers, the proposed topology enables direct control of the real power of the high-frequency inverter.

Using Gas Tungsten Arc Welding, or TIG Welding, good quality weld can be obtained. In this process, a shielding Gas is used to avoid atmospheric contamination of the molten weld pool. In the present work, bead profile in aluminium workpiece is observed as welded by AC TIG welding under 100% argon gas shield. Effects of variation of arc frequency, current and stand-off distance on bead profile are investigated. In the experiment, the bead-on-plate welding of 14 treatments is performed on Al 1000 series aluminium plates without a filler wire utilizing Central Composite Design system of Response Surface Methodology (RSM). Gas pressure is maintained at 2 kg/cm2 with gas flow rate of 15 lit/min, welding speed of 100 mm/min, electrode diameter of 3 mm and wave balance of -25. From this investigation, it is observed that an increase in welding current increases weld penetration. These are caused by the increase in heat input with the increase in weld current and decrease in torch travel speed. An increase in stand-off distance is also observed to cause a decrease in weld penetration. Analysis of variance (ANOVA) is also performed on the observed results. Regression equations are formed relating the response to the factors (independent variables). Linear relationships are found to be quite significant for both the cases of penetration and weld bead width. Acceptable correlation coefficients (R2) more than 95% are obtained in case of depth of penetration and more than 99% in case of bead width indicating effectiveness of the results observed. [ABSTRACT FROM AUTHOR]